RxDoctor Payments Data

Brandi Jones

Family · Chillicothe, OHNPI 1285289769

Payments from drug & device makers

$1,216in general payments, 2019–2025

Across 57 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$318
  • United Therapeutics Corporation$296
  • Regeneron Healthcare Solutions, Inc.$237
  • AstraZeneca$95
  • Inspire Medical Systems, Inc.$61
  • Jazz Pharmaceuticals Inc.$57
  • plus $151 from 8 others

What the payments were for

  • Food & beverage$1,13693%
  • Education$817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,216 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$30,723
Medicare patients
266
Services billed
692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter648$499,171
Breztri AerosphereBudesonide/Glycopyr/Formoterol398$310,082
Spiriva RespimatTiotropium Bromide168$117,470
Fasenra PenBenralizumab19$105,290
Breo ElliptaFluticasone/Vilanterol166$82,334
Stiolto RespimatTiotropium Br/Olodaterol Hcl53$42,728
SymbicortBudesonide/Formoterol Fumarate153$42,202
Advair HfaFluticasone Propion/Salmeterol77$37,891
Combivent RespimatIpratropium/Albuterol Sulfate60$34,738
Albuterol Sulfate HfaAlbuterol Sulfate1,025$28,106
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr42$23,449
Incruse ElliptaUmeclidinium Bromide48$20,858
DuleraMometasone/Formoterol40$15,809
Fluticasone-SalmeterolFluticasone Propion/Salmeterol122$14,798
Roflumilast191$14,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$14$629,156918 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$95$361,210571 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Chillicothe

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →